Navigation Links
FDA Approves Tekturna HCT(R) as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent
Date:7/20/2009

a sugar pill included dizziness, flu-like symptoms, diarrhea, cough, and tiredness. Other less common reactions to TEKTURNA and TEKTURNA HCT include skin rash and, additionally with TEKTURNA, cough.

Disclaimer

The foregoing release contains forward-looking statements that can be identified by terminology such as "may," "will," "risk," "estimated," "committed," "potential," or similar expressions, or by express or implied discussions regarding potential future indications or labeling for Tekturna or Tekturna HCT, or regarding potential future revenues from Tekturna or Tekturna HCT. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that Tekturna or Tekturna HCT will be approved for any additional indications or labeling. Nor can there be any guarantee that Tekturna or Tekturna HCT will achieve any particular levels of revenue in the future. In particular, management's expectations regarding Tekturna and Tekturna HCT could be affected by, among other things, unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; competition in general; unexpected regulatory actions or delays or government regulation generally; government, industry and general public pricing pressures; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... CHAPEL HILL, N.C. , July 31, 2015 ... to product success in the biopharmaceutical market. Patients ... the process of selecting and switching therapies. This ... and is pushing marketers, efforts toward patient-focused marketing. ... to patient engagement, marketers have learned it,s important ...
(Date:7/31/2015)... July 31, 2015  In today,s ever-changing marketplace, call ... increasingly mobile, increasingly connected, and increasingly impatient with slow ... customer interaction channels and tools is driving call centers ... According to research by benchmarking firm, ... (OTC) segment in a call center study realize the ...
(Date:7/31/2015)... 31, 2015  Seeger Weiss LLP is reporting that on ... warning letter to C.R. Bard, the manufacturer of Inferior ... to correct violations the agency found at two of Bard,s ... the FDA cited them during Inspectional Observations that occurred on ... Tempe, AZ , location and on October 6, ...
Breaking Medicine Technology:Consumers Forcing Pharmaceutical Industry to Shift its Marketing Focus from Products to Patients 2Best Practices in Building World-Class Consumer & Over-the-Counter Call Centers 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 3
... 20, 2011 Sevocity, a division of Conceptual MindWorks, ... selected by CITIA-SC as a preferred electronic health record ... Sevocity is the leading true Internet or cloud-based EHR. ... and customizable electronic health record system with low start-up ...
... 2011 Concentric Medical, Inc., the global leader in ... announced the launch of the expanded family of Merci ... 2.0 Soft and V 3.0 Soft, through recent Ichihen ... are now approved and reimbursed in Japan.  The Merci ...
Cached Medicine Technology:Sevocity® Named Preferred EHR Vendor by CITIA-SC, South Carolina's Health IT Regional Extension Center (REC) 2Concentric Medical Launches Full Family of Merci Retrievers® in Japan 2Concentric Medical Launches Full Family of Merci Retrievers® in Japan 3
(Date:7/31/2015)... ... 2015 , ... The Mount Sinai Health System will work with Columbia Care ... related, experimental treatments. The collaboration moves into the next phase with the recent decision ... five state licenses to produce and dispense medical marijuana. , Mount Sinai and ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... BioViva USA, ... the way we treat aging diseases. , BioViva announces it has begun a ... patients with Alzheimer’s Disease (AD) and find a cure. MaxLife will grant 100% of ...
(Date:7/31/2015)... Toledo, Ohio (PRWEB) , ... July 31, 2015 ... ... U.S. District Court for the Northern District of Ohio, Western Division (Case No. ... complaint (Case No: 3:15-cv-00397), the women experienced spontaneous migration of their Implanon® implants, ...
(Date:7/31/2015)... ... 2015 , ... The Heart Fit Clinic has increased a patient's fitness level ... of 150 beats versus 100 beats, this is a big deal," says Diamond Fernandes, ... back to patients with heart disease," he adds. People with angina are able to ...
(Date:7/31/2015)... ... 31, 2015 , ... Florida Hospital Tampa has started treating ... for targeted delivery of fluids to selected sites in the peripheral vascular system. ... with the device that provides direct, local delivery of chemotherapy to the pancreas. ...
Breaking Medicine News(10 mins):Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 2Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 3Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 2Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 3Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 2Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 3Health News:Heart Fit Clinic Helps Patient Increase Fitness Level with External Counterpulsation 2Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 2Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 3Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 4
... authored by two Memorial University faculty members published in ... the Public Library// of// Science (PLoS). Drs. Amin A. ... the paper, entitled, "Prevalence of depression among house holds ... the mental health policy." ,Dr. Muhammad Gadit ...
... allow a pioneering doctor, currently under house arrest in Henan ... award for her work on behalf// of HIV/AIDS patients, it ... had permission to travel," retired professor Gao Yaojie, 79, told ... holding her under house arrest for two weeks. ...
... found supporting evidence to implicate insulin-like growth factor receptor ... ,In a previous research, Terry J. Smith, M.D. and ... immunoglobulins and IGF-1R as a cause of inflammation and ... , The discovery of these mechanisms in ...
... University have developed a novel spraying method for delivering ... a new low-cost and scaleable technique that offers needle-free ... methods. The process could one day provide a better ... related spread of HIV/AIDS in the developing world. ...
... If you are cooking with garlic, crush the pods first ... benefits and medicinal properties are well known. It has long ... folklore for preventing everything from the common cold and flu ... herbal medicine and it contains compounds shown to help prevent ...
... on Friday plan to distribute 250,000 city-branded condoms as ... the spread of HIV// and other sexually transmitted infections, ... purple and yellow package is printed in English and ... Coming together to stop HIV in D.C.' The first ...
Cached Medicine News:Health News:A Single Biological Mechanism Behind Several Autoimmune Disorders 2Health News:Scientists Partner to Develop and Distribute New Tuberculosis Vaccine 2Health News:Free Condoms Distribution to Prevent HIV in Washington 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: